GLORIA

GEOMAR Library Ocean Research Information Access

X

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Online Resource
    Online Resource
    Hepatic Iron, Serum Ferritin, 〈i〉HFE〈/i〉 Mutation, and Hepatic Fibrosis in Chronic Hepatitis C
    S. Karger AG ; 2009
    In:  Intervirology Vol. 52, No. 5 ( 2009), p. 239-246
    Details
    In: Intervirology, S. Karger AG, Vol. 52, No. 5 ( 2009), p. 239-246
    Abstract: 〈 i 〉 Objectives: 〈 /i 〉 We studied the status of hepatic iron deposition and its relationship with blood iron indices, liver histology, and 〈 i 〉 HFE 〈 /i 〉 gene mutations in Korean patients with chronic hepatitis C (CH-C). 〈 i 〉 Methods: 〈 /i 〉 105 patients with CH-C who underwent pretreatment liver biopsy were consecutively enrolled. The hepatic iron deposition, histological activity and fibrosis were assessed by appropriate pathological scoring systems, clinical data including serum iron indices, and 〈 i 〉 HFE 〈 /i 〉 gene mutation. 〈 i 〉 Results: 〈 /i 〉 Hepatic iron deposition was found in 37 patients (35%), which was not significantly associated with degree of hepatic fibrosis or steatosis. The serum ferritin level was elevated in 27% of the patients and was an independent factor associated with hepatic iron deposition by logistic regression; however, it was not significantly associated with hepatic fibrosis either. Only H63D heterozygote was found in 6 out of 48 patients (12.5%), which was not different from the prevalence of H63D mutation in the Korean population (8.5%). 〈 i 〉 Conclusions: 〈 /i 〉 Hepatic iron deposition was uncommon and mild in Korean CH-C. Neither hepatic iron deposition nor serum ferritin were significantly related to the severity of hepatic fibrosis, which does not support the significant role of iron in the progression of hepatic fibrosis.
    Type of Medium: Online Resource
    ISSN: 0300-5526 , 1423-0100
    URL: Article
    DOI: 10.1159/000228547
    RVK:
    XA 10000
    Language: English
    Publisher: S. Karger AG
    Publication Date: 2009
    detail.hit.zdb_id: 1482863-7
    SSG: 12
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 2
    Online Resource
    Online Resource
    The Prognostic Value of Sex-Determining Region Y-Box 2 and CD8+ Tumor-Infiltrating Lymphocytes in Limited-Stage Small-Cell Lung Cancer
    S. Karger AG ; 2021
    In:  Oncology Vol. 99, No. 8 ( 2021), p. 528-538
    Details
    In: Oncology, S. Karger AG, Vol. 99, No. 8 ( 2021), p. 528-538
    Abstract: 〈 b 〉 〈 i 〉 Background: 〈 /i 〉 〈 /b 〉 Sex-determining region Y-box 2 (SOX2) is a transcriptional factor that drives embryonic stem cells to neuroendocrine cells in lung development and is highly expressed in small-cell lung cancer (SCLC). However, the prognostic role of SOX2 and its relationship with tumor-infiltrating lymphocytes (TILs) has not been determined in SCLC. Herein, we assessed the expression of SOX2 and CD8+ TILs to obtain insights into the prognostic role of SOX2 and CD8+ TILs in limited-stage (LS)-SCLC. 〈 b 〉 〈 i 〉 Methods: 〈 /i 〉 〈 /b 〉 A total of 75 patients with LS-SCLC was enrolled. The SOX2 expression and CD8+ TILs were evaluated by immunohistochemistry. 〈 b 〉 〈 i 〉 Results: 〈 /i 〉 〈 /b 〉 High SOX2 and CD8+ TIL levels were identified in 52 (69.3%) and 40 (53.3%) patients, respectively. High SOX2 expression was correlated with increased density of CD8+ TILs ( 〈 i 〉 p 〈 /i 〉 = 0.041). Unlike SOX2, high CD8+ TIL numbers were associated with significantly longer progression-free survival (PFS; 13.9 vs. 8.0 months, 〈 i 〉 p 〈 /i 〉 = 0.014). Patients with both high SOX2 expression and CD8+ TIL numbers ( 〈 i 〉 n 〈 /i 〉 = 29, 38.7%) had significantly longer PFS and overall survival (OS) compared to those from the other groups (median PFS 19.3 vs. 8.4 months; 〈 i 〉 p 〈 /i 〉 = 0.002 and median OS 35.7 vs. 17.4 months; 〈 i 〉 p 〈 /i 〉 = 0.004, respectively). Multivariate Cox regression analysis showed that the combination of high SOX2 expression and CD8+ TIL levels was an independent good prognostic factor for OS (HR = 0.471, 95% CI, 0.250–0.887, 〈 i 〉 p 〈 /i 〉 = 0.02) and PFS (HR = 0.447, 95% CI, 0.250–0.801, 〈 i 〉 p 〈 /i 〉 = 0.007) in SCLC. 〈 b 〉 〈 i 〉 Conclusions: 〈 /i 〉 〈 /b 〉 Evaluation of the combination of SOX2 and CD8+ TIL levels may be of a prognostic value in LS-SCLC.
    Type of Medium: Online Resource
    ISSN: 0030-2414 , 1423-0232
    URL: Article
    DOI: 10.1159/000516444
    RVK:
    XH 3305
    Language: English
    Publisher: S. Karger AG
    Publication Date: 2021
    detail.hit.zdb_id: 1483096-6
    detail.hit.zdb_id: 250101-6
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 3
    Online Resource
    Online Resource
    Prognostic Significance of Pretreatment 〈sup〉18〈/sup〉F-FDG PET/CT in Patients with Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma Treated by Radioimmunotherapy Using 〈sup〉131〈/sup〉I-Rituximab
    S. Karger AG ; 2013
    In:  Acta Haematologica Vol. 130, No. 2 ( 2013), p. 74-82
    Details
    In: Acta Haematologica, S. Karger AG, Vol. 130, No. 2 ( 2013), p. 74-82
    Abstract: 〈 b 〉 〈 i 〉 Aims: 〈 /i 〉 〈 /b 〉 It was the aim of this paper to identify prognostic factors in patients with relapsed or refractory B-cell non-Hodgkin's lymphomas, treated by radioimmunotherapy (RIT) with radioiodinated human/murine chimeric anti-CD20 monoclonal antibody rituximab ( 〈 sup 〉 131 〈 /sup 〉 I-rituximab). 〈 b 〉 〈 i 〉 Methods: 〈 /i 〉 〈 /b 〉 Twenty-four patients were enrolled prospectively and were treated with unlabeled rituximab 70 mg and a therapeutic activity (median 7.3 GBq) of 〈 sup 〉 131 〈 /sup 〉 I-rituximab. Contrast-enhanced 〈 sup 〉 18 〈 /sup 〉 F-FDG PET/CT scans were performed before and after 1 month of RIT. Tumor sizes and maximum standardized uptake values (SUV 〈 sub 〉 max 〈 /sub 〉 ) of scans were measured. 〈 b 〉 〈 i 〉 Results: 〈 /i 〉 〈 /b 〉 Four of the 24 patients survived. High SUV 〈 sub 〉 max 〈 /sub 〉 in a pretreatment scan was found to be related to poorer overall survival (OS) and progression-free survival (p = 0.04 and 0.02, respectively). Furthermore, a large tumor size in a pretreatment scan was associated with poorer OS but not with progression-free survival (p 〈 0.01 and p = 0.07, respectively). By multivariate analyses, a high SUV 〈 sub 〉 max 〈 /sub 〉 , a large tumor size in a pretreatment scan and diffuse large B-cell lymphoma histology were significantly associated with poorer OS [p = 0.04/hazard ratio (HR) = 3.54, p 〈 0.01/HR = 5.52, and p = 0.02/HR = 3.38, respectively). 〈 b 〉 〈 i 〉 Conclusion: 〈 /i 〉 〈 /b 〉 SUV 〈 sub 〉 max 〈 /sub 〉 and tumor size determined by a pretreatment 〈 sup 〉 18 〈 /sup 〉 F-FDG PET/CT result as significant predictors of OS in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma treated by RIT.
    Type of Medium: Online Resource
    ISSN: 0001-5792 , 1421-9662
    URL: Article
    DOI: 10.1159/000346436
    Language: English
    Publisher: S. Karger AG
    Publication Date: 2013
    detail.hit.zdb_id: 1481888-7
    detail.hit.zdb_id: 80008-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 4
    Online Resource
    Online Resource
    Stereotactic Body Radiation Therapy Using Three Fractions for Isolated Lung Recurrence from Colorectal Cancer
    S. Karger AG ; 2009
    In:  Oncology Vol. 76, No. 3 ( 2009), p. 212-219
    Details
    In: Oncology, S. Karger AG, Vol. 76, No. 3 ( 2009), p. 212-219
    Abstract: 〈 i 〉 Objective: 〈 /i 〉 To determine the feasibility of stereotactic body radiotherapy (SBRT) using 3 fractions for isolated colorectal lung metastases. 〈 i 〉 Methods: 〈 /i 〉 From June 2003 to December 2006, 13 cases of isolated pulmonary metastasis from colorectal cancer were treated by SBRT due to an inoperable state (7 patients), or the patient’s refusal to undergo surgical excision (6 patients). All patients underwent chemotherapy for salvage treatment. SBRT doses ranged from 39 to 51 Gy in 3 fractions. Nine patients had a solitary lesion, 3 patients had 2 lesions, and 1 patient had 3 lesions. Median tumor volume for the 18 lesions was 5.9 ml (range 1.6–45 ml). 〈 i 〉 Results: 〈 /i 〉 Follow-up duration was 15–57 months. Three-year overall survival, local control and progression-free survival rates were 64.7, 52.7 and 11.5%, respectively.Univariate analysis showed that total internal target volume was a significant prognostic factor for local control. During the follow-up, 11 of the 13 patients experienced local recurrence, distant metastasis or both. The most frequent site of failure was in a nontargeted lung region. No severe complication was attributed to SBRT. 〈 i 〉 Conclusion: 〈 /i 〉 Our study suggests the potential feasibility of SBRT for selected patients with 1–3 small metastatic nodules. A further larger-scale study is required to define the indications for SBRT in cases with isolated pulmonary metastasis from colorectal cancer.
    Type of Medium: Online Resource
    ISSN: 0030-2414 , 1423-0232
    URL: Article
    DOI: 10.1159/000201932
    RVK:
    XH 3305
    Language: English
    Publisher: S. Karger AG
    Publication Date: 2009
    detail.hit.zdb_id: 1483096-6
    detail.hit.zdb_id: 250101-6
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...